The study provides evidence that ICG fluorescence may serve as a sensitive intraoperative adjunct for identifying potentially positive sarcoma margins; it is only an inference, requiring prospective validation, that combining ICG with surgeon judgment could improve resection decisions and ultimately reduce local recurrence.

The study provides observational evidence that a shorter InO-to-HCT interval and greater InO exposure identify patients at increased post-transplant risk; it supports—but does not prove—the hypothesis that delaying HCT beyond 50 days when clinically feasible, limiting InO cycles, or adapting conditioning and monitoring could reduce SOS and improve outcomes.

The record provides associative evidence that pediatric palliative care involvement correlates with several advance-planning and end-of-life outcomes; it supports, but does not establish, the hypothesis that earlier systematic integration of palliative care during phase I trial enrollment could improve shared decision-making and goal-concordant end-of-life care.

The record supports standardising asparaginase monitoring and hypersensitivity management to help maintain adequate treatment exposure; it is reasonable but not demonstrated here to infer that implementation could reduce avoidable underexposure and improve outcomes or toxicity management.

The record establishes only a feasibility-testing plan; it is hypothesised, but not yet demonstrated, that accessible workbook-, audio-, video-, and telephone-guided CBT could improve parental well-being and reduce depression, anxiety, or post-traumatic stress after childhood cancer treatment.

The record supports risk-stratified management emphasizing organ-preserving oncologic surgery and optimized platinum-based chemotherapy; it is reasonable—but not demonstrated by outcome data in this abstract—to hypothesize that this approach could maintain disease control while reducing treatment-related toxicity.

The reported findings support—but do not establish—the hypothesis that molecularly selected pDMG subsets could be treated with GD2-directed CAR-T cells or TCR-T cells recognizing validated mutation-associated neoantigens; tumor-specific recognition, killing, safety, and clinical benefit remain untested in the supplied record.

The record provides observational evidence that this centralized program achieved favorable survival and eye-preservation outcomes in a resource-limited setting; it supports, but does not causally establish, the hypothesis that centralization, specialist collaboration, capacity building, and access to multimodal globe-salvage therapy can reduce retinoblastoma outcome disparities.

The reported evidence supports an association-based hypothesis—not a treatment recommendation—that pretreatment plasma EBV DNA might help identify pediatric patients in whom chemotherapy dose reduction is more or less appropriate; prospective studies must establish whether biomarker-guided dosing preserves survival and reduces toxicity.

The evidence shows that presentation acuity is associated with mortality and partially mediates the observed Black–White survival disparity; it therefore supports, but does not test, the hypothesis that earlier diagnosis, improved pre-treatment stabilization, or targeted management of cardiovascular and respiratory compromise could reduce part of this disparity.

The record establishes that SCCIP-N is being evaluated against an active control with psychosocial and physiological outcomes; it is hypothesized, but not yet demonstrated, that delivery by nurses will reduce family PTSS while improving scalability, quality of life, sleep, and related psychosocial outcomes.

The supplied review reports preclinical pathway-based and limited clinical-observation signals for several TCM-derived interventions; it can therefore be hypothesized—but is not established—that selected, standardized compounds might complement conventional thyroid-cancer treatment by modulating tumor signaling or immunity, pending pediatric-specific safety studies and rigorous randomized trials.